{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4785, 
        4799
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3912, 
        3935
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6884, 
        6904
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3965, 
        3992
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3997, 
        4002
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4118, 
        4123
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4211, 
        4215
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4331, 
        4335
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4526, 
        4530
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6687, 
        6692
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6723, 
        6728
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6749, 
        6753
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6784, 
        6788
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6825, 
        6829
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6849, 
        6854
      ]
    }
  ], 
  "Lymphatic System Location (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4514, 
        4524
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4606, 
        4616
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6830, 
        6845
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6855, 
        6869
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        652, 
        681
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6579, 
        6614
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6656, 
        6682
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4045, 
        4051
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4156, 
        4162
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4258, 
        4264
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4368, 
        4374
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4458, 
        4464
      ]
    }
  ], 
  "Neoplasm Grade-Score Name (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4801, 
        4814
      ]
    }
  ], 
  "Neoplasm Score Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4815, 
        4820
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4775, 
        4784
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6737, 
        6745
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6797, 
        6805
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6873, 
        6881
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6729, 
        6736
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6789, 
        6796
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3994, 
        3995
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4115, 
        4116
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4208, 
        4209
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4328, 
        4329
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4414, 
        4415
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4511, 
        4512
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4603, 
        4604
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4696, 
        4698
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6684, 
        6685
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6720, 
        6721
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6746, 
        6747
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6781, 
        6782
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6806, 
        6807
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6822, 
        6823
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6846, 
        6847
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6870, 
        6871
      ]
    }
  ], 
  "Synoptic Report Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5061, 
        5078
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PathSys|Associated Pathologists, LLC d/b/a PathGroup^44D0934312^CLIA|eMARCPlus|TN Cancer Registry|20170919125859||ORU^R01^ORU_R01|201709191258590001|P|2.5.1|TN||||||||VOL_V_40_ORU_R01-CCR1^NAACCR_CP\nOBR|1||17-UR-003928^PathSys^44D0934312^CLIA|11529-5^SURGICAL PATH REPORT^LN|||20170807000000|||||||20170807000000|&Soft Tissue, other than tumor,mass,lipoma,debride, Prostate, Needle Biopsy, Soft Tissue, other than tumor,mass,lipoma,debride, Prostate, Needle Biopsy, Urethra, Biopsy, Lymph Node, Biopsy, Lymph Node|1750382727^^^^^^MD^^CMS^D^^^NPI||||||20170810000000|||F||||||C61^Malignant neoplasm of prostate^I10|1770637266&&&&&&&&CMS\n\n\n\n\n\n\n\nPath report.gross description\n\n1. Right posterior vascular pedicle. Received fresh is a fragment of tan-brown tissue that measures 8 x 0.5 x 0.2 cm. The specimen is entirely submitted for frozen section diagnosis. 2. Right lateral prostate. Received in formalin is a pink-tan tissue fragment measuring 1.2 x 0.8 x 0.5 cm. The specimen is inked blue and submitted along with part 1 for frozen section diagnosis. 3. Left posterior vascular pedicle. Received fresh is a tan soft tissue fragment that measures 0.5 x 0.4 x 0.3 cm. The specimen is entirely submitted for frozen section diagnosis. 4. Left lateral prostate. Received in formalin is a fragment of tan tissue measuring 1 x 0.5 x 0.3 cm. The specimen is inked yellow and entirely submitted for frozen section diagnosis. 5. Periurethral. Received in formalin is a tan-pink tissue fragment measuring 0.6 x 0.4 x 0.2 cm. The specimen is inked orange and entirely submitted for frozen section diagnosis. 6. Received designated #6 left obturator lymph nodes is a single portion of yellow- tan fatty tissue which is 50 x 15 x 8 mm with a palpable lymph node. Lymph node is serially sectioned and reveals no grossly evident mass lesions. The lymph node is entirely submitted for frozen section diagnosis. Summary of sections: 6FSC, 1/1. (WJL) 7. Received fresh designated \"right obturator lymph node\" is a yellow-tan fatty portion of tissue which is 25 x 10 x 8 mm. Serially sectioned revealing a white-tan firm lymph node. Representative portion is submitted for frozen section diagnosis and additional sections are submitted following fixation. Summary of sections: 7FSC, 2/1. (WJL) The remainder of the nodal tissue is submitted in cassette A. 4/1. 8. Received in formalin labeled \"Charles M. Terrell\" and \"prostate\" and consists of a radical prostatectomy with attached bilateral seminal vesicles and vas deferens having a weight of 66 g. the right and left vas deferens measure 5.0 cm in length and have an average diameter of 0.5 cm. The right seminal vesicle is 2.7 x 1.0 x 0.6 cm and the left seminal vesicle is 3.0 x 1.1 x 0.6 cm. Sectioning of the seminal vesicles reveals a lobulated cystic cut surface filled with pale to tan fluid. The prostate measures 4.8 cm right to left, 4.2 cm apex to base, and 3.8 cm anterior to posterior. The external surface is markedly cauterized along the base, mid anterior and apex. Attached along the posterior left side is a portion of adherent fatty tissue measuring 3.0 cm in greatest dimension. The prostate is inked as follows: Right side is green, left side is blue. Serially sectioning apex to base reveals a pink-tan glistening lobulated cut surface with suspicious firm tan-white areas located along the left mid posterior aspect, this area measures 1.0 cm in greatest dimension. Representative sections are submitted as follows and as per diagram: 8A-8K, right prostate submitted from apex to base, 1/1 each; 8L-8W, left prostate submitted from apex to base, 1/1 each; 8X, right apical margin, 4/1; 8Y, left apical margin, 4/1; 8Z and 8AA, right base, 8A, 4/1; 8AA, 3/1; 8AB and 8AC, left base, 8AB, 4/1; 8AC, 3/1; 8AD, right seminal vesicle and right vas deferens margin, 2/1; 8AE, left seminal vesicle and left vas deferens margin, 2/1. (AC2/SB20/cc6)\n\n\nPath report.relevant Hx\n\nHistory - Prostate cancer\n\n\nPath report.final diagnosis\n\n1. Right posterior vascular pedicle, excision:     Benign fibrovascular and fibroadipose tissue.     Negative for tumor. 2. Right lateral prostate, excision:     Benign fibroadipose tissue.     Negative for tumor. 3. Left posterior vascular pedicle, excision:     Benign fibrovascular and fibroadipose tissue.     Negative for tumor. 4. Left lateral prostate, excision:     Benign fibrovascular and fibroadipose tissue. 5. Soft tissue, periurethral, excision:     Benign fibromuscular tissue.     Negative for tumor. 6. Lymph node, left obturator, excision:     One benign lymph node.     Negative for tumor. 7. Lymph node, right obturator, excision:     One benign lymph node.     Negative for tumor. 8. Prostate, seminal vesicles, and vasa deferentia, radical prostatectomy:     Prostatic adenocarcinoma, Gleason score 4+5=9 (Grade Group 5).     The tumor involves the margin.     The tumors are organ confined, but extraprostatic extension cannot be       evaluated in areas of positive margin.     The seminal vesicles and vasa deferentia are negative for tumor. CANCER CHECKLIST: PROSTATE GLAND: Radical Prostatectomy 3.000.001.1000043 Prostate Size  Prostate Weight (g): 66grams  Prostate Size in Centimeters (cm): 4.8cm  Additional Dimension in Centimeters (cm): 4.2cm, 3.8cm TUMOR  Histologic Type: Acinar adenocarcinoma Histologic Grade  Gleason Pattern: Gleason pattern  Percentage of Pattern 5: 10-20%  Primary Gleason Pattern: Pattern  Secondary Gleason Pattern: Pattern 5  Total Gleason Score: 9  Grade Group: Grade group 5  Intraductal Carcinoma (IDC): Present Tumor Extent  Tumor Quantitation: Estimated percentage of prostate involved by tumor (specify %)  Estimated percentage of prostate involved by tumor (specify %): 60%  Extraprostatic Extension (EPE): Not identified, but cannot evaluate in area of positive margin  Urinary Bladder Neck Invasion: Not identified  Seminal Vesicle Invasion: Not identified Accessory Findings  Treatment Effect: No known presurgical therapy  Lymphovascular Invasion: Not Identified MARGINS  Margins: Involved by invasive carcinoma  Margin Limitations: Non-limited (>= 3 mm)  Location of Positive Margin(s): Left anterior, Apical LYMPH NODES  Number of Lymph Nodes Involved: None identified  Number of Lymph Nodes Examined: 2 PATHOLOGIC STAGE CLASSIFICATION (pTNM, AJCC 8th Edition)  Primary Tumor (pT)#: pT2x: Organ confined, but not evaluable in areas of positive margin  Regional Lymph Nodes (pN): pN0: No positive regional nodes  Distant Metastasis (pM)#: Not applicable - pM cannot be determined from the submitted specimen(s)\n\n\nPath report.microscopic examination\n\nMicroscopic examination is performed.\n\n\nPath report.site of origin\n\n1. Right posterior vascular pedicle 2. Right lateral prostate 3. Left posterior vascular pedicle 4. Left lateral prostate 5. Periurethral 6. Left obturator nodes 7. Right obturator node 8. Prostate\n\n\nPath report.comments\n\nComments - Dominant nodule: Gleason 4+5=9 with approximately 10-20% pattern 5 localized on the left side posterior laterally extending from the apex to the mid. The tumor is associated with areas of intraductal carcinoma. Secondary nodules: Multiple secondary nodules of Gleason 3+3=6 are identified throughout the prostate. Margins: A secondary tumor nodule involves a peripheral margin anterior laterally on the left side towards the apex and focally involves the apical margin. The overall summed length of positive margin is approximately 4 mm. The highest Gleason grade at the margin is Gleason grade 3. Tumor Extent: The tumors are organ confined, but extraprostatic extension cannot be evaluated in areas of positive margin. The seminal vesicles and vasa deferentia are negative for tumor. Overall, the tumor is involves approximately 60% of the prostatic volume. Definitive lymphatic invasion is not identified. A focus adjacent to the dominant tumor nodule demonstrates tumor within lymphatic spaces, but this finding is favored to be a consequence of artifactual displacement. Multiple additional H and E levels are examined in this focus. Gleason scores can be grouped and range from Grade Group 1 (most favorable) to Grade Group 5 (least favorable).\n\n\n"
}